13.2 Financial Management, Drug Plans, and Marketing
Key Takeaways
- Gross margin is sales minus cost of goods sold, and net profit is what remains after operating expenses, so a high-volume prescription can carry a positive margin and still be unprofitable to fill.
- Inventory turnover measures how many times inventory is sold and replaced in a year; low turnover ties up capital and raises the risk of expiry.
- Canadian drug coverage is a patchwork of provincial and territorial plans, federal programs such as Non-Insured Health Benefits, private insurance, and out-of-pocket payment.
- Special authority or limited use mechanisms restrict reimbursement of higher-cost drugs to defined clinical criteria, and the pharmacist often initiates the request.
- Marketing of a pharmacy service is bounded by professional advertising standards: it must be truthful, verifiable, and must never create pressure to purchase an unnecessary health product.
13.2 Financial Management, Drug Plans, and Marketing
Exam Focus: Financial and marketing management sit inside the pharmacy management subcategory of the BSA area. Items test the vocabulary of pharmacy economics, how a Canadian patient's drug costs are actually paid, and where professional advertising limits lie.
The Financial Vocabulary of a Pharmacy
| Term | Definition | Why it matters |
|---|---|---|
| Revenue | Total income from prescriptions, services, and front-shop sales | The top line only |
| Cost of goods sold | Acquisition cost of the product sold | The largest single cost in a pharmacy |
| Gross margin | Revenue minus cost of goods sold | Measures pricing and purchasing effectiveness |
| Operating expenses | Wages, rent, utilities, insurance, software, professional fees | Wages are the largest operating cost |
| Net profit | Gross margin minus operating expenses | What the business actually earns |
| Cash flow | Timing of money in and out | A profitable pharmacy can still fail if third-party payments lag behind purchasing |
| Accounts receivable | Amounts owed, chiefly by third-party payers | Slow receivables strangle cash flow |
Prescription income in Canada comes from a professional (dispensing) fee plus a markup on drug cost, with the fee frequently capped by a provincial plan. Because the fee is largely fixed while the time required varies, a complex prescription requiring intervention can consume far more resource than its revenue, which is why professional services with their own remuneration have become important to pharmacy viability.
Cost control levers include labour scheduling matched to workload, generic substitution where permitted, purchasing discipline, expiry management, and reduction of rework caused by errors and rejected claims.
Inventory Management
Inventory is normally the largest asset on a pharmacy's balance sheet and, unmanaged, its largest source of loss.
Inventory turnover = cost of goods sold divided by average inventory value. A turnover of 12 means inventory is sold and replaced roughly monthly. Low turnover means capital is tied up in stock that is not selling and is aging toward expiry; excessively high turnover risks stock-outs and lost prescriptions.
Practical tools:
- ABC analysis. Class A items are the small proportion of products producing most of the value and are counted and managed most closely; class C items are numerous but low value and are managed loosely.
- Minimum and maximum levels and automated reordering tied to actual dispensing history rather than to intuition.
- First-expiry-first-out rotation with a monthly short-dated review and a documented process for returns and credits.
- Controlled substance inventory requires perpetual records, secure storage, and reconciliation under the Controlled Drugs and Substances Act and its regulations; losses and thefts must be reported to Health Canada within the required timeframe.
- Shrinkage from theft, expiry, and unclaimed prescriptions is tracked as a specific loss category.
How Canadians Pay for Drugs
Canada's Canada Health Act covers medically necessary hospital and physician services, but outpatient prescription drugs sit largely outside it. The result is a patchwork.
| Payer | Description |
|---|---|
| Provincial and territorial plans | Cover defined populations — typically seniors, social assistance recipients, and residents with catastrophic drug costs — each with its own formulary, deductible, and copayment |
| Federal programs | Non-Insured Health Benefits for eligible First Nations and Inuit clients; plans for veterans, the Canadian Armed Forces, the Royal Canadian Mounted Police, federal inmates, and resettled refugees |
| Private insurance | Employer-sponsored plans covering a large share of working Canadians, with copayments, annual maxima, and managed formularies |
| Out of pocket | The remainder, including the uninsured and the underinsured |
| National pharmacare | Federal legislation has begun a first phase of single-payer coverage, implemented through bilateral agreements with provinces and territories, initially for contraception and diabetes medications |
Formulary and access mechanisms the pharmacist works with daily:
- Formulary listing — the drug is reimbursed for any approved indication.
- Limited use or special authority — reimbursement only where defined clinical criteria are met, usually requiring a code or an application before the claim will pay.
- Prior authorisation in private plans — an equivalent process managed by the insurer.
- Generic pricing policies negotiated nationally through the pan-Canadian Pharmaceutical Alliance, which sets prices for many common generics.
- Health technology assessment conducted by Canada's national drug agency, which recommends whether public plans should list a new drug and on what terms.
When a drug is not covered, the pharmacist's options are to identify a covered therapeutic alternative and propose it to the prescriber, initiate the special authority process, apply for a manufacturer patient support or compassionate access program, or check eligibility for another plan the patient has not enrolled in. Cost is a clinical variable: an unaffordable prescription is an adherence problem waiting to happen, and the conversation belongs at the point of dispensing rather than after the patient has quietly stopped.
Marketing Within Professional Boundaries
Marketing a pharmacy legitimately includes describing the professional services available, their value, and how to access them. Every Canadian regulatory authority constrains it, and the constraints are examinable.
Advertising must be truthful, accurate, verifiable, and not misleading. It must not create unjustified expectations of results, exploit vulnerability or fear, use testimonials in a way the regulator prohibits, or offer inducements that encourage unnecessary use of health products or the transfer of prescriptions for reasons unrelated to care. Provinces restrict or prohibit incentives such as loyalty points on prescriptions precisely because they can influence where and how often a patient fills.
Direct-to-consumer advertising of prescription drugs is tightly restricted in Canada under the Food and Drugs Act: advertising to the public may name the product or state the condition treated, but not both, which is why Canadian advertisements either identify the brand without stating its use or describe a condition and direct the viewer to a physician. Advertising of Schedule I prescription drugs to the public is otherwise prohibited.
The professional test for any promotional activity is straightforward: does it help patients make informed decisions about care they need, or does it push products they do not? A pharmacist's commercial and professional roles coexist, and where they conflict, the professional obligation and the patient's interest prevail.
A pharmacy has annual cost of goods sold of $2,400,000 and an average inventory value of $200,000. What is its inventory turnover?
A patient's prescription for a higher-cost biologic is rejected by the provincial plan with a message indicating the drug requires defined clinical criteria to be met. This mechanism is best described as:
Which statement about advertising prescription drugs to the Canadian public is correct?
A pharmacy plans a promotion offering loyalty points for every prescription transferred from a competitor. What is the principal professional concern?